Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Markóczy, Zsolt, Sárosi, Veronika, Kudaba, Iveta, Gálffy, Gabriella, Turay, Ülkü Yilmaz, Demirkazik, Ahmet, Purkalne, Gunta, Somfay, Attila, Pápai-Székely, Zsolt, Rásó, Erzsébet, Ostoros, GyulaVolume:
18
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-018-4283-z
Date:
December, 2018
File:
PDF, 587 KB
english, 2018